The European Union’s highest court sided with Illumina, agreeing that the European Commission had no authority to review the acquisition of liquid biopsy company Grail. The ruling comes after Illumina stopped challenging antitrust litigation, opting to instead spin out Grail as a standalone company.
The post Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But It Nullifies Hefty Fine appeared first on MedCity News.
